Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Acitretin + prednicarbate is a combination of two dermatological agents used for the treatment of skin disorders, particularly those involving inflammation, hyperproliferation, and keratinization such as psoriasis. Acitretin is an oral retinoid that modulates epidermal cell proliferation and differentiation by binding to nuclear retinoic acid receptors, leading to anti-inflammatory and antiproliferative effects. Prednicarbate is a medium-potency topical corticosteroid that reduces inflammation, itching, and redness by inhibiting multiple inflammatory cytokines through glucocorticoid receptor activation. The combination aims to leverage the systemic effects of acitretin with the local anti-inflammatory action of prednicarbate for enhanced efficacy in managing moderate-to-severe skin conditions[1][4][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on acitretin + prednicarbate.